Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Eos Therapies, Inc.
San Diego, California, United Stateseostherapies.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Currently advancing TLR2/9 antagonist Eos-003 through preclinical development. Recently sold EMS-312, a TLR-2 antagonist molecule, to Empyrean Therapeutics for cancer treatment.
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Partnerships
Empyrean Therapeutics (transaction completed in October 2024)
Beyond the preview
Go deeper on Eos Therapies, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eos Therapies, Inc..